|
Disease due to Parvoviridae
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken altogether these data suggest that the p102 protein may be a candidate for a transformation-sensitive cellular marker and for a negative regulator of parvovirus replication.
|
2557856 |
1989 |
|
Autosomal Recessive Polycystic Kidney Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genomic structure of the gene for the human P1 protein (MCM3) and its exclusion as a candidate for autosomal recessive polycystic kidney disease.
|
10780780 |
2000 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The results from competition radioimmunoassay showed that binding of MAb 19-24 to SAA p102 on sarcoma cell membranes was inhibited by scFV1924.
|
10953354 |
2000 |
|
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
The results from competition radioimmunoassay showed that binding of MAb 19-24 to SAA p102 on sarcoma cell membranes was inhibited by scFV1924.
|
10953354 |
2000 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Nude mice who received injections of HEK 293 cells stably transfected with MCM3 formed tumors in 6 weeks.
|
15623617 |
2004 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Our study indicates that determination of MCM3 expression level will facilitate the assessment of many different human malignancies in tumor diagnosis, and MCM3 is involved in multiple types of human carcino-genesis.
|
15623617 |
2004 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We identified a minichromosome maintenance 3 (MCM3) gene that was overexpressed in various human cancers, including leukemia, lymphoma, and carcinomas of the uterine cervix, colon, lung, stomach, kidney and breast, and malignant melanoma.
|
15623617 |
2004 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified a minichromosome maintenance 3 (MCM3) gene that was overexpressed in various human cancers, including leukemia, lymphoma, and carcinomas of the uterine cervix, colon, lung, stomach, kidney and breast, and malignant melanoma.
|
15623617 |
2004 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified a minichromosome maintenance 3 (MCM3) gene that was overexpressed in various human cancers, including leukemia, lymphoma, and carcinomas of the uterine cervix, colon, lung, stomach, kidney and breast, and malignant melanoma.
|
15623617 |
2004 |
|
Childhood Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified a minichromosome maintenance 3 (MCM3) gene that was overexpressed in various human cancers, including leukemia, lymphoma, and carcinomas of the uterine cervix, colon, lung, stomach, kidney and breast, and malignant melanoma.
|
15623617 |
2004 |
|
Brain Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma.
|
15671553 |
2005 |
|
Meningioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found a significant increase in MCM2 (8 fold), MCM3 (5 fold), MCM4 (4 fold), MCM5 (4 fold), MCM6 (3 fold), and MCM7 (5 fold) expressions in meningiomas.
|
19877719 |
2010 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Four studies attempted to define the prognostic signature of skin melanoma but only one based the study on the primary tumor resulting in heterogenous signatures with a minimal overlap (MCM3 and NFKBIZ).
|
20177751 |
2010 |
|
Cutaneous Melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Four studies attempted to define the prognostic signature of skin melanoma but only one based the study on the primary tumor resulting in heterogenous signatures with a minimal overlap (MCM3 and NFKBIZ).
|
20177751 |
2010 |
|
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples.
|
20661220 |
2010 |
|
Childhood Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples.
|
20661220 |
2010 |
|
Adult Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples.
|
20661220 |
2010 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, deregulation of MCM2, MCM3 and MCM7 expression might be involved in MB tumorigenesis and we revealed undefined roles of these MCMs in control of MB cell migration and invasion.
|
20661220 |
2010 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
MYB can up-regulate MCM3 (minichromosome maintenance 3) and MCM7 expression; PGR can suppress BCL2 (B-cell lymphoma 2) expression; MYC can inhibit TGFB2 (transforming growth factor, beta 2) expression.
|
23098454 |
2012 |
|
Papillary thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCM3 protein expression in follicular and classical variants of papillary thyroid carcinoma.
|
23821456 |
2014 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry method, MCM3 protein expression levels were compared in FVPTC, classic variant of papillary thyroid carcinoma (CVPTC), and multi-nodular goiter (MNG) tissues in a group of 32 cases.
|
23821456 |
2014 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MCM3 expression was found to be up-regulated in glioma and correlated with overall survival in patients with WHO grade III tumor.
|
25046975 |
2014 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of MCM 2, MCM3 and MCM7 mRNA correlated with poor outcome and may be clinically useful molecular prognostic markers in glioma.
|
25046975 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
There was a statistically significant difference between SHH (p = 0.0064), STAT3 (p = 0.0003), and MCM3 (p = 0.0257) when all tumors were compared and a higher expression in parenchyma for all tumors when stroma and parenchyma were compared (p < 0.05).
|
26790448 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Our findings indicate that although both MCM3 and Ki-67 represent reliable markers of cellular proliferation in OSCC, as MCM3 expression does not appear to be influenced by external factors, this protein may emerge as a novel marker of cellular proliferation in these types of tumors.
|
27258565 |
2018 |